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Intramedullary spinal cord metastasis (ISCM) is the rarest type of CNS involvement by systemic malignant tumours. Optimal
management of patients with ISCMs remains ambiguous. Based on two cases reported from our department, we focused on the
strategy for intramedullary spinal cord metastases surgery.
1.Introduction
Intramedullary spinal cord metastases (ISCMs) are a rare
complication of malignancy and have been identiﬁed in 0.9–
2.1% of all neoplasm autopsies. ISCMs are often asymp-
tomatic and clinically aﬀect only 0.1–0.4% of all cancer
patients. One-quarter of ISCM patients have leptomeningeal
carcinomatosis, and one-third have concomitant brain
metastases [1–5]. Additionally, ISCMs commonly create
solitary lesions, constitute 8.5% of all central nervous system
metastases, and comprise 4% to 9% of all spinal cord
tumours. On the contrary, intracerebral metastases occur
in 20–50% of all cancer patients, and multiple lesions
develop in 30–50%. Despite the existence of tissue perfusion
diﬀerences, the distribution of metastases in the brain and
spinal cord has not been satisfactorily explained.
Optimal management of patients with ISCMs is diﬃcult
due to the wide variety of clinical situations and the lack
of controlled studies on the results of diﬀerent therapeutic
options. Therapeutic options for ISCMs include microsur-
gical excision; radiotherapy, currently mainly stereotactic
radiotherapy; chemotherapy; palliative therapy, particularly
steroids. Many authors have advocated radiation therapy,
preferably for radiosensitive metastases such as small cell
carcinoma, breast cancer, or lymphoma[1, 4, 6, 7]. From
our point of view, surgery could be considered an optimal
therapeutic approach for ISCMs, even accompanied by an
acceptable postoperative functional outcome.
2.Materialsand Methods
In the recent ten years, there has been substantial progress
in oncotherapy, microsurgery, and MRI availability. We
researched ISCM cases in Pubmed during this period,
including retrospective analyses and meta-analyses. This
resulted in limited bias due to the inclusion of ISCM surgery
cases from the previous period. Both spinal extradural and
primary brain metastases were beyond the scope of this
paper and were excluded. Finally, cases of ISCMs managed
by surgery were selected.
3.Resultsand Discussion
Eleven papers concerned with ISCM surgery have been
published in the last ten years. Except for one review
article, only case reports were found. However, two more
abundant studies with 13 and 19 patients were also dis-
covered. To sum up, a total of ﬁfty-four patients under-
went surgery. Laminectomy or osteoplastic laminotomy
with tumour excision was performed in all but one. In
this single case, only palliative decompressive laminectomy
was done [8]. None of these developed new neurological
deﬁcits, and partial neurological improvement was achieved
[1, 2, 4].
In the literature, tumour removal was identiﬁed as
complete in 47 patients and incomplete in 5 patients, and
surgical biopsy was done in 2 patients [1–10].2 International Journal of Surgical Oncology
Figure 1: Intramedullary metastasis of colorectal carcinoma.
3.1. Incidence and Pathophysiology. Lung metastases, which
account for about half of the ISCMs, were by far the most
common source. The incidences of the various tumour pri-
maries were lung (especially small cell carcinoma) 29–54%,
breast11–14%,kidney6–9%,colorectal3–5%,melanoma 6–
9%, lymphoma 4%, thyroid 2%, ovarian 1%, and approx-
imately 3% were categorized as secondary to an unknown
primary [11].
ISCMs are mainly disseminated by the arterial route
(Figure1). Meningeal carcinomatosis occurs by CSFseeding.
Tumour cells inﬁltrate the Virchow-Robin spaces of vessels,
penetrating the spinal cord and pial membrane and invading
the spinal cord parenchyma (Figure 2). A third mechanism
is the direct invasion from contiguous structures. Spread
through thevertebral venousplexus(Batson’splexus) during
Valsalva manoeuvre enabling retrograde blood ﬂow to the
spinalcordis alsopossible.ISCMsconcurredwithmeningeal
carcinomatosis in 15–55% of cases. Finally, direct invasion
from contiguous structures is also conceded. Although the
dura protects the cord from invasion by malignant tumours,
metastasis expansion from the spinal extradural space or
nerve roots through the dura and into the cord has been
suggested (Figure 3)[ 1, 12].
The above-mentioned discrepancy between the frequen-
cies of brain and intramedullary metastases would be
partly explained as follows. One-third of the cardiac output
through the large vessels under high pressure directs to the
brain, while the spinal cord receives arterial supply from
small, low-pressure, and convoluted vessels. The medullary
arteries branchoﬀtheaortaatrightangles, whilethecerebral
arteries are almost a direct extension of the aorta, thus
favouring embolic seeding [9].
3.2. Symptoms. Due to the advances in imaging and thera-
peutic modalities prolonging the survival of cancer patients,
the probability of discovering ISCMs increases.
Figure 2: Cauda equine inﬁltration by breast carcinoma.
Figure 3: Direct intraspinal cancer invasionalong nerve root.
ISCMs may be considered as an infrequent ﬁnding
at advanced stage of disease, usually accompanying rapid
progression of systemic cancer. But in much rarer cases,
ISCMs are the initial presentation of malignancy. This
occurred in 22.5% to 39% of ISCM cases [1, 4, 7].
Prompt diagnosis is important for treatment rationale.
However, exact diagnosis of ISCMs may be diﬃcult despite a
positive history of malignancy, because clinical ﬁndings do
not help to distinguish ISCMs from other lesions such as
epidural metastasis, paraneoplastic necrotizing myelopathy,
radiation myelopathy, or from a coincidence of nutritional,
demyelinative, inﬂammatory, or vascular myelopathies [1,
7].
The published median intervals between the onset of
ISCM-related neurological symptoms and the ﬁnal diagnosis
varied from 1 week to 2 weeks to 7 weeks to 9 weeks, with the
greatest range being 17 months [1, 2, 4, 6, 7].
At diagnosis, about 20% of patients are ambulatory
independent, 40% are ambulatory with assistance, and the
remaining 40%arenonambulatory.Nevertheless,oneauthorInternational Journal of Surgical Oncology 3
somberly reported that three-fourths of patients developed
a complete neurological deﬁcit during less than one month
from the onset of neurological symptoms [1, 2]. The
described rapid symptom progression is elicited by the lim-
ited resistance of spinal cord tissue and vascular structures
involved by an increasing tumour size and perifocal oedema.
ISCMs predominantly aﬀect elderly patients who commonly
have serious comorbidities and, thus, myelopathy presents
more acutely in them.
The range, pattern, and deterioration of the neurological
status are based on ISCM location and volume. Clinically,
ISCMs are manifested by pain, weakness, sensory loss,
and incontinence. Brown-Sequard syndrome or complete
spinal cord transection is nearly equally present. Pain
is usually followed by sensory and sphincter disturbance
[1, 2, 11].
Weakness was present in 91% of patients at diagnosis of
ISCMs. Sensory loss (79%), sphincter dysfunction (60%),
back pain (38%), and radicular pain (24%) were also com-
mon. Brown-Sequard syndrome or pseudo-Brown-Sequard
syndrome was seen in 23–45% of cases. Asymptomatic cases
have also been described (1%) [1, 2, 7, 10, 11].
3.3. Diagnosis. Currently, spinal magnetic resonance imag-
ing (MRI) is applied routinely for the diagnosis of ISCMs.
Beforethe eraof MRI,only5% were recognized before death.
Other imaging techniques (CT, PET/CT, and angiography)
are of marginal signiﬁcance. Single ISCM is most commonly
seen (94%) although multiple ISCMs (6%) are also encoun-
tered [1, 7].
Due to the general infrequency of ISCMs and the time
elapsed from the ﬁrst cancer attack, tumour duplicity, that is
primary intraspinal neoplasm, would be the preferred diag-
nosis. ISCMsare typicallycharacterized by rapid progression
of symptoms in contrast to the relatively slow growth of
primary intramedullary tumours (gliomas, ependymomas,
etc.).
At the time of diagnosis, 55% of ISCM patients had
systemic metastases, and an additional 41% had brain
metastases. The other types reported included bone (24%),
leptomeningeal (17%), pulmonary (13%), lymph node
(12%), hepatic (8%), adrenal (2%), splenic, sacral, and rib
metastases.
Cytological investigation of CSF is usually negative.
Retrospectively, malignant cells in CSF were conﬁrmed only
in 11 patients. Nearly, in all ISCM patients (95%), CSF
protein level was abnormally elevated. In older studies, one-
half to two-thirds of meningeal carcinomatosis cases had
malignant cells in CSF analysis. Thus, lumbar puncture and
CSF analysis have limited signiﬁcance for the diagnosis of
ISCMs [1, 2, 4, 7].
3.4. Surgery and Survival. Currently, surgical approach is
more precise and less invasive and thus allows spinal cord
tumour excision with an acceptable morbidity rate. The
purpose is decompression of functional neural tissue and
histological conﬁrmation of the tumour. Some authors
documented that complete neurological deﬁcit developed in
75% of ISCM patients within approximately one month.
Giventhisresult,surgicalresectioncanbeperformedinthese
selected cases [1, 2].
Advanced technologies such as MR/CT navigation or
ultrasound for tumour location, cavitron ultrasonic surgical
aspirator and laser for dissection, and intraoperative mon-
itoring of somatosensory evoked potentials have allowed
limited myelotomy and a relatively safe tumour removal.
Radicality also depends on tumour histology. Patients with
adenocarcinoma had longer survival rates than those with
poorly diﬀerentiated carcinomas. Poorly diﬀerentiated carci-
nomas and sarcomas are diﬃcult to be managed by radical
surgery due to the absence of a clear cleavage plane. In
these cases, some authorsrecommend biopsy,decompressive
laminectomy, and adjuvant therapy [2, 7, 13].
Many reports favoured radiotherapy (RT). However,
given the rarity of ISCMs, no controlled studies comparing
surgery and RT were undertaken.
The median survival of patients with ISCMs depends
on several conditions. The survival was inﬂuenced by the
preoperative neurological status, nature of the primary
cancer, and presence of systemic and/or CNS metastases, but
the diﬀerences were mostly without statistical signiﬁcance.
Nevertheless, surgery statistically prolonged survival more
than doubly (7.4 versus 2.6 months). According to other
authors, the median survival extends beyond 9.4 months
when patients undergo surgery versus 5 months when
conservative treatment is performed. Regarding primary
cancer, the median survivals are 5.5 months and 1.0
month for breast cancer and lung cancer, respectively. Most
patients succumbed to progression of the primary cancer
[2, 8, 9].
The neurological status improved in 58% (11/19) of
operatedpatients.Onthecontrary, ISCMpatientswith brain
metastaseshavealifeexpectancyofabout3to4monthsfrom
the time of diagnosis [14].
3.5. Adjuvant Therapy. Focal radiation is used as an adjunct
treatment for residual disease within the resection cavity.
Postoperatively, RT (30Gy) is used in the resection site.
The majority of ISCMs published were only treated with
radiotherapy or chemotherapy. The aim of RT is to arrest
tumor growth and prevent further neurological deﬁcit. RT
is considered for radiosensitive carcinomas such as small
cell lung carcinoma, breast carcinoma, or lymphoma. The
reported six-month survival rate of the cases treated with
radiation therapy is less than 20%. The response to RT is
minimal if paraplegia supervenes [14, 15].
Moreover, RT is controversial in many cases. The risk
of radiation myelitis can occur after signiﬁcant radiation
exposure. The radiation tolerance of the spinal cord alone
is substantially limited, and knowledge of the safe amount of
radiation delivered to the spinal cord involved by metastasis
is lacking[16].Fractionatedradiotherapyiseﬀectiveparticu-
larly when the patients are not neurologically compromised.
Currently, much more targeted RT such as stereotactic
radiotherapy is recommended. Some authors even advise
to irradiate the entire spinal cord, but with unknown bone
marrow toxicity and a questionable improvement in the
outcome.4 International Journal of Surgical Oncology
Most of these patients underwent chemotherapy and
biologicaltherapy during theﬁrst cancerattack,butthese are
not applicable in ISCM management. These modalities do
not pass through the blood-spinal cord barrier. Chemother-
apy has no further eﬀect on survival [7, 17–19].
Another therapeutic modality is steroid therapy. Patients
with rapidly progressive symptoms of cord compression and
a high risk of rapid deterioration are suitable for treatment
with high-dose steroids. This may decrease the pain and
cause transient improvement in neurological conditions.
Steroidssuppressperifocaloedemaandnormalize theblood-
spinal cordbarrier, which decreasestumoursize butdoesnot
inﬂuence survival. Steroid therapy provides additional time
for the diagnostic process as well as controls or minimizes
the oedema after surgery or RT [2].
4.Conclusion
Diagnosis should be made as early as possible and surgical
resection should be considered as the primary treatment
whenever feasible, particularly in the case of rapidly progres-
sive neurological deﬁcits.
Our strategy involves aggressive surgery in selected
ISCM patients, particularly those presenting with previously
undiagnosed or limited primary tumours. Before choosing
surgery, the clinical condition, age of the patient, primary
tumour pathology, and presence of other secondary lesions
have to be assessed. Finally, the expected survival is esti-
mated, and the rationale for the surgical procedure as well
as the approach and extent of resection are obtained. An
intraoperative monitoring is auxiliary method to facilitate
safe and radical tumour resection.
CNS metastases are extra-axial tumours. The neoplasm
characteristics play a major role. ISCMs are often well
circumscribed, cystic or with a cystic part, and encapsulated.
Cystic tumours or cystic tumour components facilitate
surgical extirpation because the cystic component often
reaches the spinal cord surface. Therefore, the tumor can
be easily removed without disruption to normal neural
structures. However, gross total resection of solid tumour
withpreservationofneurologicalfunctionsispossible.Inthe
selected patients, the quality of life can be improved. Surgery
should not be undertaken in cases of complete paraplegia.
The authorhas had two published experiences of ISCMs.
Firstly,therewasapatientwithsolitaryISCMasinitialsignof
colorectal carcinoma. Due to fast neurological deterioration
the patient underwent ISCM surgery followed solution of
primary tumour and extraneuronal metastases. Secondly,
there was a patient with history of breath carcinoma. She
has been already treated for extraneuronal metastases several
years. A neurological deﬁcit evolved, and solitary ISM was
revealed. Forrelatively good prognosis of this carcinoma, the
patient underwent surgery.
Although the number of cases is small, analysis of
literature data suggests that, in some patients with ISCMs,
surgical treatment is of relevance.
The median progression-free survival was 13 weeks
(range 3–96 weeks), and the median survival time after
surgery was 27 weeks (range 3–148 weeks). The median
survival of patients with adenocarcinoma metastases was 42
weeks. The median survival was 21 weeks and 8 weeks for
sarcomas and poorly diﬀerentiated carcinomas, respectively
[1, 2, 7, 20].
RT is considered as an adjunct treatment after surgery.
Some authors have proposed the possibility that
chemotherapy for intracerebral metastases can cross the
disrupted blood-brain barrier and extrapolated this to
ISCMs [17–19]. When compared, the blood-brain barrier
and the blood-spinal cord barrier are not entirely identical.
For example, their permeabilities are reduced by steroids.
PatientswithISCMshavealimitedresponse totreatment
and a very unfavourable prognosis. Every eﬀort should be
made for eﬀective palliation and prevention of paraplegia.
In our view, it is of essential importance to minimize the
time from the ﬁrst symptoms to diagnosis and to select
patients who would beneﬁt most from surgery. Ultimately,
cooperation among the neurosurgeon, neuroradiothera-
pist, neuro-oncologist, neuropathologist, and physiothera-
pist is absolutely mandatory for an eﬀective therapeutic
process.
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